» Articles » PMID: 35257270

LncRNA XIST Facilitates Hypoxia-induced Myocardial Cell Injury Through Targeting MiR-191-5p/TRAF3 Axis

Overview
Publisher Springer
Specialty Biochemistry
Date 2022 Mar 8
PMID 35257270
Authors
Affiliations
Soon will be listed here.
Abstract

Myocardial infarction is one of the most lethal diseases in cardiovascular diseases. In the present work, we aimed to elucidate the molecular and functional association long non-coding RNA (lncRNA) X-inactive specific transcript (XIST), microRNA (miR)-191-5p, and TNF receptor-associated factor 3 (TRAF3). Human cardiomyocyte primary cells (HCMs) were stimulated by hypoxia to establish a model of myocardial injury in vitro. The relative expressions of XIST, miR-191-5p, and TRAF3 were measured using quantitative real-time polymerase chain reaction (qRT-PCR) assay. The capabilities of proliferation and apoptosis were determined using cell counting kit (CCK-8) and flow cytometry assays, respectively. The molecular interactions were verified using dual luciferase assay. The protein contents of TRAF3, Bcl-2, and Bax were calculated using western blot assay. XIST was significantly increased, but miR-191-5p was reduced in hypoxia-treated HCMs compared to that in control group. Either downregulated XIST or enforced miR-191-5p markedly enhanced cell viability and restrained cell apoptotic rate in hypoxia-treated HCMs. Mechanistically, XIST directly interacted with miR-191-5p to competitive releasing TRAF3 expression. Importantly, overexpression of TRAF3 dramatically diminished the protective effects of XIST knockdown on hypoxia-triggered HCMs injury. Collectively, our data elucidated a novel "lncRNA XIST/miR-191-5p/TRAF3" molecular network in vitro, indicating that the reduced lncRNA XIST-protected HCMs from hypoxia-induced cell injury by regulating miR-191-5p/TRAF3 signaling, which might provide some convincing evidences for further understanding the influences of "lncRNA-miRNA-mRNA" network in the development of MI.

Citing Articles

KLF9 aggravates the cardiomyocyte hypertrophy in hypertrophic obstructive cardiomyopathy through the lncRNA UCA1/p27 axis.

Ding D, Zhao G Int J Exp Pathol. 2025; 106(2):e12526.

PMID: 39909852 PMC: 11798666. DOI: 10.1111/iep.12526.


Serum MicroRNA-191-5p Levels in Vascular Complications of Type 1 Diabetes: The EURODIAB Prospective Complications Study.

Bellini S, Guarrera S, Matullo G, Schalkwijk C, Stehouwer C, Chaturvedi N J Clin Endocrinol Metab. 2023; 109(1):e163-e174.

PMID: 37552780 PMC: 10735284. DOI: 10.1210/clinem/dgad468.


LOXL1-AS1 Aggravates Myocardial Ischemia/Reperfusion Injury Through the miR-761/PTEN Axis.

He W, Duan L, Zhang L Korean Circ J. 2023; 53(6):387-403.

PMID: 37161797 PMC: 10244188. DOI: 10.4070/kcj.2022.0301.

References
1.
Mullasari A, Balaji P, Khando T . Managing complications in acute myocardial infarction. J Assoc Physicians India. 2012; 59 Suppl:43-8. View

2.
Kim Y, Sharp S, Hwang S, Jee S . Exercise and incidence of myocardial infarction, stroke, hypertension, type 2 diabetes and site-specific cancers: prospective cohort study of 257 854 adults in South Korea. BMJ Open. 2019; 9(3):e025590. PMC: 6430026. DOI: 10.1136/bmjopen-2018-025590. View

3.
Ben-Yehuda O, Chen S, Redfors B, McAndrew T, Crowley A, Kosmidou I . Impact of large periprocedural myocardial infarction on mortality after percutaneous coronary intervention and coronary artery bypass grafting for left main disease: an analysis from the EXCEL trial. Eur Heart J. 2019; 40(24):1930-1941. DOI: 10.1093/eurheartj/ehz113. View

4.
Crossman A, DAgostino Jr H, Geraci S . Timing of coronary artery bypass graft surgery following acute myocardial infarction: a critical literature review. Clin Cardiol. 2002; 25(9):406-10. PMC: 6653855. DOI: 10.1002/clc.4960250903. View

5.
Sorensen J, Maeng M . Regional systems-of-care for primary percutaneous coronary intervention in ST-elevation myocardial infarction. Coron Artery Dis. 2015; 26(8):713-22. DOI: 10.1097/MCA.0000000000000290. View